New PPAR therapies could slow fibrosis in primary biliary cholangitis

New PPAR therapies could slow fibrosis in primary biliary cholangitis

Primary biliary cholangitis is a rare autoimmune disease that affects the liver and can progress to cirrhosis. It occurs when the immune system attacks the small bile ducts within the liver. As a result, bile builds up, leading to inflammation and progressive liver damage. Although a first-line treatment exists, 40% of patients do not respond adequately to it or cannot tolerate it, so new treatment options need to be developed.

If you liked the article, do not forget to share it with your friends. Follow us on Google News too, click on the star and choose us from your favorites.

If you want to read more Like this articles, you can visit our Science category.

Source

Leave a Reply

Your email address will not be published. Required fields are marked *